INFO

177Lu-PSMA-617 radioligand therapy in mCRPC – VISION phase 3 trial The results from the “ProPSMA” Study, that was recently published in JAMA Oncology by Prof.

The “proPSMA” study results proved the superiority of 68Ga-PSMA imaging over conventional imaging with CT and Bone Scan in Prostate Cancer Results from a randomised

https://www.youtube.com/watch?v=V27sXF4b_1k&feature=youtu.be On October 10, 2019, the FDA approved the use of 18F-DOPA in positron emission tomography to visualize dopaminergic nerve terminals in the striatum for

Carrier Added (CA) and Non-Carrier Added (NCA) Production of 177-Lu 177-Lu is a fully synthetic isotope. there are 2 ways to produce 177-Lu: The direct route

For decades, physicians and patients knew three classic treatments for cancer: Surgery Chemotherapy Radiation therapy New times have come, and new therapies are available like:

Innovative metastatic prostate cancer treatment with 177-Lu-PSMA. Prostate cancer is the most common cancer in older men (over 50) and the second cause of cancer death in